A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2016

At a glance

  • Drugs Avacopan (Primary)
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLASSIC
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Nov 2016 Accoridng to ChemoCentryx media release, positive results will be presented at the American Society of Nephrology (ASN) Kidney Week 2016
    • 08 Aug 2016 Primary endpoint ( Efficacy is evaluated based on the Birmingham Vasculitis Activity Score (BVAS ) has been met, according to a ChemoCentryx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top